Molecule to Market: Inside the outsourcing space

Building robust and scalable systems

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Orfan, President at Sharp. Kevin has been in the pharmaceutical and medical device industry for over 30 years and has incredible experience in the contract manufacturing space. He began his pharma career at Abbott Laboratories before moving to Hospira and then Pfizer CentreOne. He joined Sharp as president in 2019 and now oversees its global operations.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Kevin Orfan speaking on the importance of building robust and scalable systems and processes in a fast growing contract packaging company, especially in the current climate of the pandemic. Kevin talks about the challenges in keeping up with the rapid, global demand of new, large molecule drug products and the increasing complexity they bring. He shares how he maintains a solid work ethic by always having a plan, knowing what he can control and focusing on the value-add factors in a business as a top priority. Lastly he speaks about the direct-to-patient trend he is seeing in the industry as pharmaceutical companies become more willing to carry out clinical trial work in patient's homes.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Entrepreneurship in the life science space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeffrey Kiplinger, Co-Founder of Cohere Business Strategies and advisor and coach for entrepreneurs in the life science space. Jeffrey Co-Founded Research Operations Group in 2000, founded Averica Discovery Services in 2007, and has over 35 academic publications and holds a PhD in organic chemistry. 

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Jeffrey Kiplinger as he describes the benefit in making oneself vulnerable and putting your pride aside to seek the support of others. He advises young leaders to ask “stupid questions” and allow your mistakes to become a part of your success story. Jeffrey speaks about the changes he has seen in the sector over the years and the interesting shift towards a numbers-based system which in his opinion, has devalued the scientists at the core of operations. As a coach for entrepreneurs, Jeff covers the barriers many business professionals face when trying to start their own business in the life science sector. He offers advice and words of wisdom for those who are struggling in this difficult market. Lastly he stresses the value of the relationship with a client and explains how it can be the key to success in this industry.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Advocating for the CDMO sector

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA). Previous to launching PBOA in 2014, Gil helped launch Contract Pharma in 1999 and served as the founding editor for 15 years. Contract Pharma has since grown to become one of the most respected magazines in the industry.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Gil Roth, speaking on the tremendous impact the PBOA has made with congress and the FDA on behalf of the contract manufacturing industry. Gil offers some insight on how the PBOA has found success in influencing representatives and senators in Washington to learn about the sector and advocate on its behalf. Gil reflects on the ways the industry has changed over the past couple of decades, such as the sophistication of acquisitions and the willingness to openly outsource from a reputation standpoint. Raman and Gil identify the trends and challenges they have noticed in a time where once common business practices have been stripped away as we all adapt to this new normal. Lastly Gil speaks about his own podcast, The Virtual Memories Show, and the impact and joy it has created over the years. 

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The benefits of postponement packaging

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dexter Tjoa, CEO at Tjoapack. With a master's from Oxford University, Dexter joined Tjoapack about 5 years ago. His career has accelerated at an incredible speed since taking over the family business from his father, who founded Tjoapack over 30 years ago in the Netherlands.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Dexter Tjoa as they speak on what it has been like to take the reins of the fast growing family business as one of the youngest CEOs in the sector. Dexter describes what the selection process has been like in trying to find a finance partner to help accelerate the company’s growth. Dexter also explains how surrounding yourself with smart people who you like and who can compliment your skills and weaknesses are essential in one’s success as a leader. Lastly, he speaks on the value of postponement packaging and how contract packaging organisations are of increasing importance, rather than an afterthought for drug developers.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Taking the family-owned CDMO global

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bobby Sheng, CEO and Chairman of Bora Pharmaceuticals.  A California native and an experienced leader in the pharmaceutical industry, Bobby is skilled in international business, management, mergers & acquisitions, finance, and marketing. He graduated from University of California, Berkeley and now resides in Taiwan.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Bobby Sheng, speaking on Bobby’s time as a producer in the film industry and the lessons he gained from producing nine films. Bobby explains his key focus areas as a leader and how he tries to keep them top of mind as he progresses through his career. He also explains the importance of having the right people on your team and describes them as the best and strongest asset an organization can have. Lastly, Bobby speaks on the pharma production industry. He believes there is room to adopt efficiencies and technologies in order to move away from the archaic batch production system.  

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The increasing demand for HPAPI

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with John Ross, President at Mayne Pharma US. John Ross has spent 15 years in the pharma contract services space in senior roles following some time at Eli Lilly and PWC. He joined Mayne in 2013 as a VP and transitioned to President in 2017. Today, he oversees over 550+ people in North Carolina and has managed a huge injection of investment in the business.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest John Ross, covering the contrast from working in Big Pharma versus running high-growth contract service organisations. They also discuss the increasing demand for and challenge of handling, developing and manufacturing highly potent pharmaceutical products. Lastly they trade tips for leading a senior management team in a global business while also making time to learn and balance life outside of work. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

A CDMO on the Covid-19 frontline

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michael Quirmbach, Group Chief Executive Officer and President at Corden Pharma. Michael has been in the contract services space for 20 years. He joined Corden Pharma in 2014, holding positions as Vice President, Marketing and Sales and Chief Business Officer before becoming CEO & President in 2019. Prior to joining Corden Pharma, he held positions of increasing responsibility at AMRI, Solvias, Dr. Reddy’s and Siegfried AG.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Guest Name, Michael, covering manufacturing and supplying front-line drug products in the fight against Covd-19. They speak on transitioning a big pharma cost/profit centre mindset culture to a more agile, customer-centric, resilient, CDMO service mentality. And finally they discuss the role of continuous education, openness to cultures, goal setting and daily routines in achieving incredible career success.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Learnings from 30 years in the CDMO space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Eugene Ciolfi aka ‘Gene’, President and CEO at MedPharm. Gene has spent over 30 years in the CDMO space working for several renowned companies in senior roles along the way. It’s fair to say Gene has probably seen more than most in drug development!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gene, speaking on the transformation of the CDMO landscape over the last 30 years. They  address the many changes that have occurred but also the things that have stayed the same as time goes on. They also discuss the benefit of truly ‘value-add’ CDMOs to small and large drug developers in helping achieve pipeline success and raising the CDMO bar. Lastly Gene discusses the importance of being okay with making mistakes and addresses trust and integrity as two key pillars in the heavily regulated pharmaceutical and biotech drug development space.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The importance of positive, disruptive thinking

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Detlef Behrens, founder at Bay Pharma. A PhD pharmacist by training, Detlef is a seasoned industry professional having spent 20 years in the pharmaceutical and biotechnology space. He’s worked for several global CDMOs and now runs a biotech company. He is one of a rare breed that has seen drug development from both the CRAMS/CDMO/CMO vendor side of the fence and the sponsor side. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Detlef, speaking on what life is really like in a small virtual biotech company, how the pharmaceutical industry and its supply chain will evolve as a consequence of the current/ future pandemics and the role of a global one-stop shop CDMOs versus specialist companies. Detlef also explains the importance in disrupting the way we have done things in drug development in the past.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The value of diversity In pharma

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with  Barbara Morgan, Global Business Director for Pharma and Nutra at Lubrizol. A PhD chemist by trade, Barbara has gone from working at the Broad Institute of MIT and Harvard in 2009, to heading the CDMO and Nutra division of Lubrizol, an incredible trajectory in 10 years. Along the way, she’s headed up teams, worked in the VC/M&A space and held a variety of very interesting roles in healthcare.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Barbara Morgan, covering why it’s essential for pharmaceutical leaders to build a diverse team and the value of having mentors and sponsors both at work and outside of work. They also discuss how holding a variety of roles over time, constant learning and taking risks can help accelerate your career in the pharmaceutical industry. Lastly they speak on the increasing importance of bioavailability in modern drug development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.